

Johnson & Johnson and Subsidiaries**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

	FOURTH QUARTER				
	2012	2011	Total	Percent Change	
				Operations	Currency
Sales to customers by segment of business					
Consumer					
U.S.	\$ 1,203	1,248	(3.6) %	(3.6)	-
International	2,449	2,420	1.2	3.2	(2.0)
	3,652	3,668	(0.4)	0.9	(1.3)
Pharmaceutical					
U.S.	3,013	2,887	4.4	4.4	-
International	3,512	3,207	9.5	12.1	(2.6)
	6,525	6,094	7.1	8.5	(1.4)
Med Devices & Diagnostics					
U.S.	3,244	2,850	13.8	13.8	-
International	4,137	3,643	13.6	15.8	(2.2)
	7,381	6,493	13.7	14.9	(1.2)
U.S.	7,460	6,985	6.8	6.8	-
International	10,098	9,270	8.9	11.2	(2.3)
Worldwide	\$ 17,558	16,255	8.0 %	9.3	(1.3)

	TWELVE MONTHS				
	2012	2011	Total	Percent Change	
				Operations	Currency
Consumer					
U.S.	\$ 5,046	5,151	(2.0) %	(2.0)	-
International	9,401	9,732	(3.4)	1.9	(5.3)
	14,447	14,883	(2.9)	0.5	(3.4)
Pharmaceutical					
U.S.	12,421	12,386	0.3	0.3	-
International	12,930	11,982	7.9	13.6	(5.7)
	25,351	24,368	4.0	6.8	(2.8)
Med Devices & Diagnostics					
U.S.	12,363	11,371	8.7	8.7	-
International	15,063	14,408	4.5	8.6	(4.1)
	27,426	25,779	6.4	8.7	(2.3)
U.S.	29,830	28,908	3.2	3.2	-
International	37,394	36,122	3.5	8.4	(4.9)
Worldwide	\$ 67,224	65,030	3.4 %	6.1	(2.7)

Johnson & Johnson and Subsidiaries**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

FOURTH QUARTER

	2012	2011	Percent Change		
			Total	Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 7,460	6,985	6.8 %	6.8	-
Europe	4,603	4,279	7.6	10.4	(2.8)
Western Hemisphere excluding U.S.	1,941	1,688	15.0	18.7	(3.7)
Asia-Pacific, Africa	3,554	3,303	7.6	8.5	(0.9)
International	10,098	9,270	8.9	11.2	(2.3)
Worldwide	\$ 17,558	16,255	8.0 %	9.3	(1.3)

TWELVE MONTHS

	2012	2011	Percent Change		
			Total	Operations	Currency
U.S.	\$ 29,830	28,908	3.2 %	3.2	-
Europe	16,945	17,129	(1.1)	5.8	(6.9)
Western Hemisphere excluding U.S.	7,207	6,418	12.3	19.0	(6.7)
Asia-Pacific, Africa	13,242	12,575	5.3	6.7	(1.4)
International	37,394	36,122	3.5	8.4	(4.9)
Worldwide	\$ 67,224	65,030	3.4 %	6.1	(2.7)

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER

	2012		2011		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 17,558	100.0	\$ 16,255	100.0	8.0
Cost of products sold	6,003	34.2	5,338	32.8	12.5
Selling, marketing and administrative expenses	5,661	32.2	5,458	33.6	3.7
Research and development expense	2,331	13.3	2,155	13.3	8.2
In-process research and development	55	0.3	-	-	
Interest (income) expense, net	89	0.5	148	0.9	
Other (income) expense, net	319	1.8	2,858	17.6	
Restructuring (income) expense, net	-	-	(20)	(0.1)	
Earnings before provision for taxes on income	3,100	17.7	318	1.9	874.8
Provision for taxes on income	533	3.1	100	0.6	433.0
Net earnings	2,567	14.6	218	1.3	1,077.5
Add: Net loss attributable to noncontrolling interest	-	-	-	-	
Net earnings attributable to Johnson & Johnson	\$ 2,567	14.6	\$ 218	1.3	1,077.5
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 0.91		\$ 0.08		1,037.5
Average shares outstanding (Diluted)	2,833.4		2,768.9		
Effective tax rate	17.2 %		31.4 %		
Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)					
Earnings before provision for taxes on income	\$ 4,115	23.4	\$ 3,657	22.5	12.5
Net earnings attributable to Johnson & Johnson	\$ 3,376	19.2	\$ 3,129	19.2	7.9
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 1.19		\$ 1.13		5.3
Effective tax rate	18.0 %		14.4 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS

	2012		2011		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 67,224	100.0	\$ 65,030	100.0	3.4
Cost of products sold	21,658	32.2	20,360	31.3	6.4
Selling, marketing and administrative expenses	20,869	31.0	20,969	32.3	(0.5)
Research and development expense	7,665	11.4	7,548	11.6	1.6
In-process research and development	1,163	1.7	-	-	
Interest (income) expense, net	468	0.7	480	0.7	
Other (income) expense, net	1,626	2.5	2,743	4.2	
Restructuring (income) expense, net	-	-	569	0.9	
Earnings before provision for taxes on income	13,775	20.5	12,361	19.0	11.4
Provision for taxes on income	3,261	4.9	2,689	4.1	21.3
Net earnings	10,514	15.6	9,672	14.9	8.7
Add: Net loss attributable to noncontrolling interest	339	0.5	-	-	
Net earnings attributable to Johnson & Johnson	\$ 10,853	16.1	\$ 9,672	14.9	12.2
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 3.86		\$ 3.49		10.6
Average shares outstanding (Diluted)	2,812.6		2,775.3		
Effective tax rate	23.7 %		21.8 %		
Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)					
Earnings before provision for taxes on income	\$ 18,214	27.1	\$ 17,353	26.7	5.0
Net earnings attributable to Johnson & Johnson	\$ 14,345	21.3	\$ 13,867	21.3	3.4
Net earnings per share attributable to Johnson & Johnson (Diluted)	\$ 5.10		\$ 5.00		2.0
Effective tax rate	21.2 %		20.1 %		

(1) See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

<i>(Dollars in Millions Except Per Share Data)</i>	Fourth Quarter		% Incr. / (Decr.)	Twelve Months		% Incr. / (Decr.)
	2012	2011		2012	2011	
Earnings before provision for taxes on income - as reported	\$ 3,100	318	874.8 %	\$ 13,775	12,361	11.4 %
Net litigation loss (gain)	471	2,656		1,229	3,310	
In-process research and development	55	14		1,163	14	
Synthes integration/transaction costs and currency related	406	277		1,028	491	
Intangible asset write-downs and other adjustments	-	-		909	-	
DePuy ASR™ Hip program	83	412		110	521	
Restructuring	-	(20)		-	656	
Earnings before provision for taxes on income - as adjusted	<u>\$ 4,115</u>	<u>3,657</u>	<u>12.5 %</u>	<u>\$ 18,214</u>	<u>17,353</u>	<u>5.0 %</u>
Net Earnings attributable to Johnson & Johnson - as reported	\$ 2,567	218	1,077.5 %	\$ 10,853	9,672	12.2 %
Net litigation loss (gain)	371	2,239		1,052	2,745	
In-process research and development	59	11		743 (1)	11	
Synthes integration/transaction costs and currency related	306	338		899	477	
Intangible asset write-downs and other adjustments	-	-		701	-	
DePuy ASR™ Hip program	73	336		97	426	
Restructuring	-	(13)		-	536	
Net Earnings attributable to Johnson & Johnson - as adjusted	<u>\$ 3,376</u>	<u>3,129</u>	<u>7.9 %</u>	<u>\$ 14,345</u>	<u>13,867</u>	<u>3.4 %</u>
Diluted Net Earnings per share attributable to Johnson & Johnson - as reported	\$ 0.91	0.08	1,037.5 %	\$ 3.86	3.49	10.6 %
Net litigation loss (gain)	0.13	0.81		0.37	0.99	
In-process research and development	0.02	-		0.27	-	
Synthes integration/transaction costs and currency related	0.11	0.12		0.32	0.17	
Intangible asset write-downs and other adjustments	-	-		0.25	-	
DePuy ASR™ Hip program	0.02	0.12		0.03	0.16	
Restructuring	-	-		-	0.19	
Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted	<u>\$ 1.19</u>	<u>1.13</u>	<u>5.3 %</u>	<u>\$ 5.10</u>	<u>5.00</u>	<u>2.0 %</u>

(1) Amount includes third quarter in-process research and development charge of \$679M related to bapineuzumab IV offset by \$339M reported as net loss attributable to noncontrolling interest

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT⁽²⁾										
BABY CARE										
US	\$ 103	103	0.0%	0.0%	-	\$ 412	418	-1.4%	-1.4%	-
Intl	469	465	0.9%	3.5%	-2.6%	1,842	1,922	-4.2%	1.1%	-5.3%
WW	572	568	0.7%	2.8%	-2.1%	2,254	2,340	-3.7%	0.6%	-4.3%
ORAL CARE										
US	165	173	-4.6%	-4.6%	-	641	656	-2.3%	-2.3%	-
Intl	251	239	5.0%	6.6%	-1.6%	983	968	1.5%	6.9%	-5.4%
WW	416	412	1.0%	2.0%	-1.0%	1,624	1,624	0.0%	3.2%	-3.2%
OTC/NUTRITIONALS										
US	356	370	-3.8%	-3.8%	-	1,424	1,429	-0.3%	-0.3%	-
Intl	802	766	4.7%	5.7%	-1.0%	2,930	2,973	-1.4%	3.4%	-4.8%
WW	1,158	1,136	1.9%	2.6%	-0.7%	4,354	4,402	-1.1%	2.1%	-3.2%
SKIN CARE										
US	385	403	-4.5%	-4.5%	-	1,699	1,654	2.7%	2.7%	-
Intl	509	541	-5.9%	-3.4%	-2.5%	1,919	2,061	-6.9%	-2.0%	-4.9%
WW	894	944	-5.3%	-3.9%	-1.4%	3,618	3,715	-2.6%	0.1%	-2.7%
WOMEN'S HEALTH										
US	82	89	-7.9%	-7.9%	-	336	439	-23.5%	-23.5%	-
Intl	325	309	5.2%	9.4%	-4.2%	1,289	1,353	-4.7%	2.3%	-7.0%
WW	407	398	2.3%	5.5%	-3.2%	1,625	1,792	-9.3%	-4.0%	-5.3%
WOUND CARE/OTHER										
US	112	110	1.8%	1.8%	-	534	555	-3.8%	-3.8%	-
Intl	93	100	-7.0%	-8.0%	1.0%	438	455	-3.7%	0.6%	-4.3%
WW	205	210	-2.4%	-2.9%	0.5%	972	1,010	-3.8%	-1.8%	-2.0%
TOTAL CONSUMER										
US	1,203	1,248	-3.6%	-3.6%	-	5,046	5,151	-2.0%	-2.0%	-
Intl	2,449	2,420	1.2%	3.2%	-2.0%	9,401	9,732	-3.4%	1.9%	-5.3%
WW	\$ 3,652	3,668	-0.4%	0.9%	-1.3%	\$ 14,447	14,883	-2.9%	0.5%	-3.4%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ^{(2) (4)}

IMMUNOLOGY

	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational	Currency			Reported	Operational	Currency
US	\$ 1,448	1,401	3.4%	3.4%	-	\$ 5,972	5,751	3.8%	3.8%	-
Intl	528	395	33.7%	35.7%	-2.0%	1,902	1,047	81.7%	86.3%	-4.6%
WW	1,976	1,796	10.0%	10.4%	-0.4%	7,874	6,798	15.8%	16.9%	-1.1%
REMICADE										
US	871	776	12.2%	12.2%	-	3,583	3,276	9.4%	9.4%	-
US Exports ⁽³⁾	347	437	-20.6%	-20.6%	-	1,470	1,797	-18.2%	-18.2%	-
Intl	286	215	33.0%	34.4%	-1.4%	1,086	419	*	*	-4.5%
WW	1,504	1,428	5.3%	5.5%	-0.2%	6,139	5,492	11.8%	12.6%	-0.8%
SIMPONI										
US	72	62	16.1%	16.1%	-	292	235	24.3%	24.3%	-
Intl	109	57	91.2%	96.8%	-5.6%	315	175	80.0%	87.5%	-7.5%
WW	181	119	52.1%	54.8%	-2.7%	607	410	48.0%	51.2%	-3.2%
STELARA										
US	158	126	25.4%	25.4%	-	627	443	41.5%	41.5%	-
Intl	111	81	37.0%	40.1%	-3.1%	398	295	34.9%	42.4%	-7.5%
WW	269	207	30.0%	31.2%	-1.2%	1,025	738	38.9%	41.9%	-3.0%
OTHER IMMUNOLOGY										
US	-	-	-	-	-	-	-	-	-	-
Intl	22	42	-47.6%	-49.4%	1.8%	103	158	-34.8%	-33.0%	-1.8%
WW	22	42	-47.6%	-49.4%	1.8%	103	158	-34.8%	-33.0%	-1.8%
INFECTIOUS DISEASES										
US	236	210	12.4%	12.4%	-	974	1,401	-30.5%	-30.5%	-
Intl	620	506	22.5%	26.7%	-4.2%	2,220	1,788	24.2%	32.1%	-7.9%
WW	856	716	19.6%	22.6%	-3.0%	3,194	3,189	0.2%	4.6%	-4.4%
INTELENCE										
US	46	45	2.2%	2.2%	-	176	163	8.0%	8.0%	-
Intl	38	38	0.0%	1.7%	-1.7%	173	151	14.6%	22.2%	-7.6%
WW	84	83	1.2%	2.0%	-0.8%	349	314	11.1%	14.8%	-3.7%
LEVAQUIN/FLOXIN										
US	-	(6)	*	*	-	35	579	-94.0%	-94.0%	-
Intl	10	11	-9.1%	-10.5%	1.4%	40	44	-9.1%	-5.8%	-3.3%
WW	10	5	100.0%	97.2%	2.8%	75	623	-88.0%	-87.8%	-0.2%
PREZISTA										
US	165	143	15.4%	15.4%	-	672	529	27.0%	27.0%	-
Intl	188	173	8.7%	12.2%	-3.5%	742	682	8.8%	16.3%	-7.5%
WW	353	316	11.7%	13.6%	-1.9%	1,414	1,211	16.8%	21.0%	-4.2%
OTHER INFECTIOUS DISEASES										
US	25	28	-10.7%	-10.7%	-	91	130	-30.0%	-30.0%	-
Intl	384	284	35.2%	40.5%	-5.3%	1,265	911	38.9%	47.3%	-8.4%
WW	409	312	31.1%	35.9%	-4.8%	1,356	1,041	30.3%	37.7%	-7.4%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	% Change					% Change				
	2012	2011	Reported	Operational	Currency	2012	2011	Reported	Operational	Currency
NEUROSCIENCE										
US	601	611	-1.6%	-1.6%	-	2,611	2,617	-0.2%	-0.2%	-
Intl	1,088	1,128	-3.5%	-1.6%	-1.9%	4,107	4,331	-5.2%	-0.8%	-4.4%
WW	1,689	1,739	-2.9%	-1.6%	-1.3%	6,718	6,948	-3.3%	-0.5%	-2.8%
<u>CONCERTA/METHYLPHENIDATE</u>										
US	116	155	-25.2%	-25.2%	-	609	822	-25.9%	-25.9%	-
Intl	127	119	6.7%	8.1%	-1.4%	464	446	4.0%	8.8%	-4.8%
WW	243	274	-11.3%	-10.7%	-0.6%	1,073	1,268	-15.4%	-13.7%	-1.7%
<u>INVEGA</u>										
US	76	66	15.2%	15.2%	-	299	285	4.9%	4.9%	-
Intl	71	59	20.3%	23.0%	-2.7%	251	214	17.3%	22.0%	-4.7%
WW	147	125	17.6%	18.9%	-1.3%	550	499	10.2%	12.2%	-2.0%
<u>INVEGA SUSTENNA/ XEPLION</u>										
US	132	99	33.3%	33.3%	-	482	319	51.1%	51.1%	-
Intl	96	36	*	*	-2.4%	314	59	*	*	-5.7%
WW	228	135	68.9%	69.9%	-1.0%	796	378	*	*	-2.2%
<u>RISPERDAL CONSTA</u>										
US	103	108	-4.6%	-4.6%	-	439	443	-0.9%	-0.9%	-
Intl	255	277	-7.9%	-5.8%	-2.1%	986	1,140	-13.5%	-8.6%	-4.9%
WW	358	385	-7.0%	-5.5%	-1.5%	1,425	1,583	-10.0%	-6.4%	-3.6%
<u>OTHER NEUROSCIENCE</u>										
US	174	183	-4.9%	-4.9%	-	782	748	4.5%	4.5%	-
Intl	539	637	-15.4%	-13.7%	-1.7%	2,092	2,472	-15.4%	-11.9%	-3.5%
WW	713	820	-13.0%	-11.7%	-1.3%	2,874	3,220	-10.7%	-8.0%	-2.7%
ONCOLOGY										
US	135	95	42.1%	42.1%	-	506	331	52.9%	52.9%	-
Intl	684	468	46.2%	49.7%	-3.5%	2,123	1,717	23.6%	29.7%	-6.1%
WW	819	563	45.5%	48.5%	-3.0%	2,629	2,048	28.4%	33.3%	-4.9%
<u>DOXIL/CAELYX</u>										
US	21	10	*	*	-	43	140	-69.3%	-69.3%	-
Intl	9	29	-69.0%	-68.3%	-0.7%	40	262	-84.7%	-83.5%	-1.2%
WW	30	39	-23.1%	-22.6%	-0.5%	83	402	-79.4%	-78.6%	-0.8%
<u>VELCADE</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	502	352	42.6%	47.6%	-5.0%	1,500	1,274	17.7%	24.5%	-6.8%
WW	502	352	42.6%	47.6%	-5.0%	1,500	1,274	17.7%	24.5%	-6.8%
<u>ZYTIGA</u>										
US	114	85	34.1%	34.1%	-	463	191	*	*	-
Intl	150	67	*	*	-3.8%	498	110	*	*	-7.0%
WW	264	152	73.7%	75.8%	-2.1%	961	301	*	*	-3.7%
<u>OTHER ONCOLOGY</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	23	20	15.0%	18.8%	-3.8%	85	71	19.7%	25.5%	-5.8%
WW	23	20	15.0%	18.8%	-3.8%	85	71	19.7%	25.5%	-5.8%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	% Change					% Change				
	2012	2011	Reported	Operational	Currency	2012	2011	Reported	Operational	Currency
TOTAL OTHER										
US	593	570	4.0%	4.0%	-	2,358	2,286	3.1%	3.1%	-
Intl	592	710	-16.6%	-15.5%	-1.1%	2,578	3,099	-16.8%	-12.4%	-4.4%
WW	1,185	1,280	-7.4%	-6.8%	-0.6%	4,936	5,385	-8.3%	-5.8%	-2.5%
ACIPHEX/PARIET										
US	92	110	-16.4%	-16.4%	-	372	414	-10.1%	-10.1%	-
Intl	94	144	-34.7%	-33.9%	-0.8%	463	561	-17.5%	-11.8%	-5.7%
WW	186	254	-26.8%	-26.4%	-0.4%	835	975	-14.4%	-11.1%	-3.3%
PROCRIT/EPREX										
US	171	191	-10.5%	-10.5%	-	805	814	-1.1%	-1.1%	-
Intl	155	177	-12.4%	-11.0%	-1.4%	657	809	-18.8%	-13.7%	-5.1%
WW	326	368	-11.4%	-10.7%	-0.7%	1,462	1,623	-9.9%	-7.4%	-2.5%
OTHER										
US	330	269	22.7%	22.7%	-	1,181	1,058	11.6%	11.6%	-
Intl	343	389	-11.8%	-10.8%	-1.0%	1,458	1,729	-15.7%	-12.1%	-3.6%
WW	673	658	2.3%	2.9%	-0.6%	2,639	2,787	-5.3%	-3.1%	-2.2%
TOTAL PHARMACEUTICAL										
US	3,013	2,887	4.4%	4.4%	-	12,421	12,386	0.3%	0.3%	-
Intl	3,512	3,207	9.5%	12.1%	-2.6%	12,930	11,982	7.9%	13.6%	-5.7%
WW	\$ 6,525	6,094	7.1%	8.5%	-1.4%	\$ 25,351	24,368	4.0%	6.8%	-2.8%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	2012					2011				
	2012	2011	% Change			2012	2011	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾⁽⁴⁾										
<u>CARDIOVASCULAR CARE</u>										
US	\$ 186	191	-2.6%	-2.6%	-	\$ 752	841	-10.6%	-10.6%	-
Intl	320	349	-8.3%	-6.6%	-1.7%	1,233	1,447	-14.8%	-11.5%	-3.3%
WW	506	540	-6.3%	-5.2%	-1.1%	1,985	2,288	-13.2%	-11.1%	-2.1%
<u>DIABETES CARE</u>										
US	295	330	-10.6%	-10.6%	-	1,312	1,312	0.0%	0.0%	-
Intl	349	340	2.6%	5.2%	-2.6%	1,304	1,340	-2.7%	2.8%	-5.5%
WW	644	670	-3.9%	-2.6%	-1.3%	2,616	2,652	-1.4%	1.4%	-2.8%
<u>DIAGNOSTICS</u>										
US	258	280	-7.9%	-7.9%	-	1,025	1,091	-6.0%	-6.0%	-
Intl	272	274	-0.7%	1.3%	-2.0%	1,044	1,073	-2.7%	1.0%	-3.7%
WW	530	554	-4.3%	-3.3%	-1.0%	2,069	2,164	-4.4%	-2.6%	-1.8%
<u>INFECTION PREVENTION/OTHER</u>										
US	86	94	-8.5%	-8.5%	-	399	377	5.8%	5.8%	-
Intl	160	144	11.1%	13.6%	-2.5%	553	529	4.5%	8.2%	-3.7%
WW	246	238	3.4%	4.9%	-1.5%	952	906	5.1%	7.2%	-2.1%
<u>ORTHOPAEDICS</u>										
US	1,246	775	60.8%	60.8%	-	4,144	3,093	34.0%	34.0%	-
Intl	1,142	678	68.4%	70.1%	-1.7%	3,655	2,716	34.6%	38.7%	-4.1%
WW	2,388	1,453	64.3%	65.1%	-0.8%	7,799	5,809	34.3%	36.2%	-1.9%
<u>SPECIALTY SURGERY</u>										
US	326	327	-0.3%	-0.3%	-	1,297	1,226	5.8%	5.8%	-
Intl	329	307	7.2%	9.5%	-2.3%	1,229	1,181	4.1%	8.9%	-4.8%
WW	655	634	3.3%	4.4%	-1.1%	2,526	2,407	4.9%	7.2%	-2.3%
<u>SURGICAL CARE</u>										
US	618	639	-3.3%	-3.3%	-	2,415	2,465	-2.0%	-2.0%	-
Intl	1,049	1,055	-0.6%	1.9%	-2.5%	4,068	4,172	-2.5%	2.1%	-4.6%
WW	1,667	1,694	-1.6%	0.0%	-1.6%	6,483	6,637	-2.3%	0.6%	-2.9%
<u>VISION CARE</u>										
US	229	214	7.0%	7.0%	-	1,019	966	5.5%	5.5%	-
Intl	516	496	4.0%	6.1%	-2.1%	1,977	1,950	1.4%	3.7%	-2.3%
WW	745	710	4.9%	6.4%	-1.5%	2,996	2,916	2.7%	4.3%	-1.6%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	3,244	2,850	13.8%	13.8%	-	12,363	11,371	8.7%	8.7%	-
Intl	4,137	3,643	13.6%	15.8%	-2.2%	15,063	14,408	4.5%	8.6%	-4.1%
WW	\$ 7,381	6,493	13.7%	14.9%	-1.2%	\$ 27,426	25,779	6.4%	8.7%	-2.3%

* Percentage greater than 100%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported as U.S. sales

(4) Prior year amounts have been reclassified to conform to current year product disclosure